**Title**:Peripheral blood immunophenotype indicators for prognostic survival in acute ischemic stroke

**Authors**: Kang Lu(17856278330@163.com)1,4\*, Yong-Ran Cheng (chengyr@zjams.com.cn)2\*, Wanmao Ni3\*, Jing Du5, Yanchun Li6, Xu Wang7, Wanye Hu1, Shida Chen1, Haifeng Xu7, Hairui Wang7, Huanjuan Li7, Chaoting Zhou8, Luyang Wang2, Mingqi Zhou9, Xiangmin Tong4#, Guo-Bo Chen (chenguobo@hmc.edu.cn)3#, Ying Wang4#

Correspondence: Ying Wang, Phase I Clinical Research Center, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, 310014 Zhejiang, China.nancywangying@163.com

\*/#: These authors co-contributed to the work.

**Affiliations**:

1 Bengbu Medical College, Bengbu, 233003 Anhui, China;

2School of Public Health, Hangzhou Medical College, Hangzhou, 310013 Zhejiang, China;

3Clinical Research Institute, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, 310014 Zhejiang, China;

4Phase I Clinical Research Center, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, 310014 Zhejiang, China;

5Department of Medical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, 310014 Zhejiang, China;

6The Second Clinical Medical School of Zhejiang Chinese Medical University, Zhejiang Chinese Medical University, Hangzhou, 310053 Zhejiang, China;

7School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325035 Zhejiang, China;

8Zhejiang University of Technology, Hangzhou, 310014 Zhejiang, China;

9Hangzhou Normal University, Hangzhou, 310036 Zhejiang, China.

**ORCID**: 0000-0003-0045-3803(KL), 0000-0003-2646-560X (YRC),0000-0001-5475-8237 (GBC), 0000-0003-2121-7025(YW)

**Abstract**

**Background:** Whether peripheral blood immunophenotype indicators influence the prognosis of acute ischemic stroke remains unclear. Thus, this study aimed to investigate the relationship between peripheral blood immunophenotype indicators and prognostic survival in patients with acute ischemic stroke.

**Methods:** One-way ANOVA was used to analyze the differences in 72 immunophenotype indicators between the control group and the acute ischemic stroke group. Kaplan-Meier survival analysis was used to analyze the relationship between different immunophenotype indicators and the acute ischemic stroke group. Univariate Cox survival analysis of differences between and within groups was performed by log-rank test. Stepwise regression was used to select important immunophenotype indicators related to survival, and then multivariate analysis was performed to calculate hazard ratio (HR) and confidence interval (CI).

**Results:** A total of 416 patients assessed for eligibility who included 250 individuals who diagnosed the acute ischemic stroke and 160 individuals who diagnosed the other mild neurological disease but not vascular diseases. Among 72 immunophenotype indicators, 54 immunophenotypes indicators were statistically significant (*p*<0.05). 16 immunophenotypes indicators were found to be statistically significant (log-rank test, *p*<0.05) for univariate survival analysis, among 8 immunophenotype indicators that have great influence on survival. Multivariate analysis showed that 6 immunophenotypes indicators had a greater impact on survival separately absolute number of TH cell(HR:11.13,95%CI:1.84-17.17, *p* =0.01), absolute number of naive CD8+ T cell(HR:1.31,95%CI:1.02-1.66, *p* =0.03), absolute number of CD16+ NK cells(HR:13.0,95%CI:6.00-18.98, *p* =0.01), absolute number of CD16- NK cells(HR:11.01,95%CI:1.90-13.64, *p*=0.01), the percentage of effector CD4+ T cell(HR:1.21,95%CI:1.02-1.40, *p*=0.02) and the percentage of naive CD8+ T cell(HR:1.09,95%CI:1.03-1.38, *p* =0.01).

**Conclusions:** The present study identified that immunophenotype biomarkers in peripheral blood may have great clinical significance in the acute ischemic stroke. Predictors of early acute stroke outcome may contribute to stroke treatment. The prognostic value of peripheral blood biomarkers in patients with the acute ischemic stroke may be of great significance to clinical routine.

**Keywords** acute ischemic stroke, immunophenotype, prognostic survival.

**Trial registration number:** ChiCTR2000040207

**Introduction**

Cerebral vascular disease including cerebral ischemic stroke remains a major cause of long-term disability and death worldwide. Ischemic stroke accounts for approximately 80% of stroke incidences1, which is a leading cause of death and physical disability word-wide. However, treatments that effectively limit the tissue injury and brain dysfunction are still elusive, and the current therapeutic approaches for the acute treatment only rely on blood flow restoration by thrombus lysis or mechanical removal2, treatments that effectively limit the tissue injury and brain dysfunction are still elusive. Prediction of functional outcome after ischemic stroke is crucial for patients and clinicians for allocation of healthcare resources and optimization of patient care.13Stroke produces profound local and systemic immune responses that engage all major innate and adaptive immune compartments.4 However, whether immunophenotype indicators influence the prognosis of acute ischemic stroke remains unclear. Over the past years, inflammatory response after cerebral ischemia has risen broad interests5. Poststroke immune regulation including accumulation of microglia and infiltration of the ischemic hemisphere by macrophages, lymphocytes, dendritic cells (DCs) and neutrophilic flux. The extent of neuronal damage seems to correlate with the degree of innate immune activity and numerous studies have demonstrated the critical role of the cellular and humoral immune system in postischemic brain injury6. Therefore, as a pivotal role in cerebral vascular disease, immune system requires extensive studies.

Circulating neutrophils predominate in humans(50–70%), while in rodents, circulating leukocytes mainly consist of lymphocytes (75–90%). Besides potential differences between humans and animals, poststroke neuroinflammation and the efficacy of anti-inflammatory treatments differ substantially among commonly used animal stroke models suggesting that this heterogeneity contributes to the translational failure. Altogether, single studies analyzing the post-ischemic immune cell infiltration revealed inconclusive results.

In experimental animal models such as mice and rat, the crucial functions of invading immune cells and proinflammatory cytokines have been well 7-10investigated7-10, while the whole immune reaction pictures in human ischemic stroke is barely unknown. Even the poststroke immune regulation were mainly focused on local lesion, such as resident immune cells and cytokines, whereas, the activation in peripheral blood circulation were limited. Given the differences of systemic blood and immune responses in between animal models and human, it poses a challenge how to transform discoveries in animal models into ‘druggable’ mechanisms of ischemic stroke. Therefore, little is known on the reaction of systemic immune response after ischemic stroke, and is still controversial whether the immune response has benefits or hazards.

Here we used immunophenotyping assays by single-cell mass cytometry to comprehensively and functionally characterize the systemic immune response within 24 hours after ischemic stroke in peripheral blood samples from 255 patients. We investigated the relationship between overall survival and immunophenotyping of peripheral blood, which included lymphocyte, monocyte, DC cell and NK cell subsets. In addition, the survival rate were followed to assess the relationship between immune response and prognosis. After ischemic stroke the systemic immune response were inhibited, a factor that led to poor prognosis and lower overall survival rate. These set of immunophenotyping with peripheral blood provide a promising and easily accessible post-stroke biomarkers to predicts functional outcomes after ischemic stroke.

**Patients and Methods**

**Study Design and Population**

A retrospective study was conducted on a primary cohort of the patients who diagnosed as acute ischemic stroke and other mild neurological diseases but not vascular diseases between January 2016 and December 2019 in Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang Province, China. The patients were eligible for enrollment if they had ischemic stroke, and then were evaluated by stroke specialists. A total of 500 patients assessed for eligibility that included 300 individuals were diagnosed with acute ischemic stroke, were regarded as the acute ischemic group, another 200 individuals were diagnosed with other mild neurological disease but not related to any vascular diseases, were regarded as the ‘control group’, including **i**) 78 with myathenia gravis; **ii**) 60 with dizziness; **iii**) 32 with peripheral neuropathy; **iv**) 30 with Parkinson’s disease. 75 patients were excluded with lack of complete basic information or laboratory indicators, 415 participants were conducted by immunophenotyping assays using single-cell mass cytometry. (**Figure 1**).This study was conducted in accordance with the Declaration of Helsinki and approved by the institutional ethics committee of Zhejiang Provincial People’s Hospital. All the authors vouch for the validity of the data and adherence to the protocol.

**Baseline characteristics and laboratory measurements**

The baseline characteristics of the participants included age, sex, body mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), the history of hypertension, smoking, alcohol, and the history with antihypertension drugs and lipid-lowering drugs. Height and weight were measured with the participants standing without shoes or heavy outer garments. BMI was calculated by dividing weight in kilograms by height in meters squared.

The samples of the peripheral blood were collected within 24 hours after admission. Laboratory variables included red blood cell, white blood cell, platelet count, hemoglobin, hematocrit, and mean corpuscular volume, were measured on a Coulter Counter STKS sample testing system (Coulter Corp, America) according to standard procedures provided by Sysmex Corporation (Japan). Total protein (TP), albumin (ALB), total bilirubin (TBIL), direct bilirubin (DBIL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glucose (GLU), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglyceride, serum creatinine levels were measured using standard protocols provided by Beckman-Coulter Experimental System Corporation (America).

**Flow Cytometry**

Within 24 hours after admission, the peripheral blood samples in patients with confirmed acute ischemic stroke were collected, anticoagulated with heparin and stained. Each sample was divided into five tubes, antibodies were added to each flow tube in turn according to the detection scheme, and then 100 microliters of peripheral blood were taken and incubated in the absence of light for 15 minutes, then 1× ammonium chloride lysate (0.15M NH4CL, 10mM NaHCO3, 1mM EDTANa2) was fully mixed and not exposed to light for 10 minutes, and finally 500g centrifugation for 5 minutes, then the supernatant was removed, and the samples were re-suspended and mixed with 200 microliters of PBS, and detected on the computer. More detailed trial procedures were described in the reference.11 The detection scheme was shown in **Table S1**.

**Statistical analysis**

The continuous variables were summarized as, means and standard deviations, or medians and interquartile ranges, and the categorical variables were expressed as frequencies and percentages. Continuous variables were compared using the Student’s *t* test and categorical variables were compared using the Fisher’s exact test or chi-square test, as appropriate. One-way ANOVA was used to analyze the differences in 72 immunophenotype indicators between the control group and the acute ischemic stroke group. Kaplan-Meier survival analysis was used to analyze the relationship between different immunophenotype indicators and the acute ischemic stroke group. Univariate Cox survival analysis of differences between and within groups was performed by log-rank test. Stepwise regression was used to select important immunophenotype indicators related to survival based on Akaike information criterion (AIC), established multivariate survival model and then multi-factor analysis was performed to calculate hazard ratio (HR) and confidence interval (CI). All tests were two-tailed, with a significant *p*-value threshold was defined as 0.05. “Survival” and “Survminer” packages were mainly used in the survival analysis. Statistical analysis were conducted in R statistical software( version 3.6.1; http://www.Rproject.org) (reference).

**Results**

**Baseline Data and Laboratory Measurements**

From January 2016 through December 2019, a total of 500 patients were enrolled, 417 met the eligibility criteria. The basic characteristics of the subjects were shown in **Table 1**. The mean age of the acute ischemic stroke group and the control group (mild neurological disease but not related to any vascular diseases) was 70.2 ± 18.4 years and 67.2 ± 13.3 years respectively(not statistically significant *p*=0.14. Of them, 173 (67.8%) and 72 (44.4%) were males in the acute ischemic stroke group and the control group, respectively (statistically significant, *p*<0.05). BMI was 23.8 ± 4.1 and 22.8 ± 5.2 respectively (not statistically significant *p*>0.05). And there were significant differences with the history of hypertension, smoking, alcohol and using antihypertension drugs and lipid-lowering drugs (*p*<0.05).

As shown in the **Table 2**, The acute ischemic stroke group had higher concentration of ALT, AST, GLU, TBIL, DBIL, IBIL, CREA and ALP compared with the control group, which were statistically significant (*p*<0.05). The acute ischemic stroke patients had lower concentration of PLT, LDL-C, HDL-C, TC, ALB and triglyceride compare with the control group which was statistically significant (*p*<0.05). However, all these laboratory indicators were within the normal reference range. In addition, the *p*-value of RBC, WBC, Hemoglobin, Hematocrit, MCV and TP were more than 0.05, with no statistically significant.

**Immunophenotyping assays**

To compare the differences of immunophenotype indicators between the acute ischemic stroke and the control group, up to 72 immunophenotype indicators in peripheral blood were examined using one-way ANOVA. The distribution diagram of the number of statistical differences was shown in **Figure S1**. It could be evidently seen from that there were more immunophenotype indicators with statistical differences than those without statistical differences. Among 72 immunophenotype indicators, 54 immunophenotypes indicators were statistically significant (*p*<0.05) and 18 immunophenotypes indicators were not statistically significant (*p*>0.05), as shown in **Table 3**.

In T cell subsets, all CD4+ T cell subsets were statistically significant (*p*<0.05), all CD8+ T cell subsets were statistically significant except absolute number of Central memory CD8+ T cells and the percentage of Effector CD8+ T cells. In Treg cell subsets, absolute number of Memory Treg cells, the percentage of Naive Treg cells, absolute number of Naive Treg cells and absolute number of Activated Treg cells were not statistically significant (*p*>0.05), the rest immunophenotypic indicators were statistically significant (*p*<0.05). And all monocytes subsets, dendritic cells (DCs) subsets and cytotoxic T cells were statistically significant (*p*<0.05). Among the T helper(Th) cell subsets, all immunophenotypic indicators were statistically significant (*p*<0.05) except the percentage of Th2 cells. In B cell subsets, all immunophenotypic indicators were not statistically significant (*p*>0.05). In NK cell subsets, all immunophenotypic indicators were statistically significant (*p*<0.05) except the percentage of NK cells, the percentage of CD16+ NK cells and the percentage of CD56low NK cells. **Comparison of overall survival between the acute ischemic stroke group and the control group**

To confirm the survival probability between the acute ischemic stroke and the control group, the volunteers were followed up to 5years. No doubt, the overall survival of patients with the acute ischemic stroke (0.60) was significantly lower than that of the control group (0.89), which had [distinct](javascript:;)ly statistical significance (log-rank test, *p*<0.0001) as was shown in **Figure 2**.

**Univariate Cox survival analysis with the acute ischemic stroke**

As was shown in **Figure S2**, by analyzing of 54 different immunophenotypes indicators of the acute ischemic stroke group, to seek some immunophenotypes indicators with clinical significance by using univariate survival analysis. 16 immunophenotypes indicators were found to be statistically significant (log-rank test, *p*<0.05). To further investigate whether the 16 immunophenotypes indicators between the acute ischemic stroke and the control group, as shown in **Figure S3**, using One-way ANOVA analysis, demonstrated all these immunophenotypes indicators were statistically significant.

Among the most distinguished 16 immunophenotypes indicators, by calculating the hazard ratio (HR) of each immunophenotype indicator, 8 immunophenotype indicators that have positive association on survival, including: The ratio of non-classical monocyte (HR 2.3), The ratio of total monocyte (HR 2.1), The ratio of classical monocyte (HR 2.08), The ratio of Effector memory CD8+ T cell (HR 2.05), The ratio of Cytotoxic T cell(HR 2.03), Absolute number of Non-classical monocyte (HR 2.0), Absolute number of total monocyte (HR1.98), Absolute number of CD56high NK cells (HR 1.08) (**Figure 3)**. Besides, it was seen that the percentage of non-classical monocyte was the most significant immunophenotypes indicators with the survival probability, which could decrease the survival probability.

To further analyze ,54 immunophenotypes indicators were divided into high- and low-value subgroup according to the average in the acute ischemic stroke group respectively; then the volunteers were followed. As shown in **Figure S4**, which concluded that 11 immunophenotypes indicators were statistically significant (log-rank test, *p*<0.05) by using univariate survival analysis (**Figure S4**). As shown in **Figure 4**, the higher expression of 5 immunophenotypes indicators which are absolute number of Th cell (8.3y vs 4.2y, *p*=0.049), absolute number of total Treg cell (9.1y vs 4.2y, *p*=0.026), absolute number of Th1 cell (10y vs 4.1y, *p*=0.029), absolute number of central memory CD4+ T cell (9.1y vs 4.2y, *p*=0.015)and absolute number of naive CD8 + T cell (9.1y vs 5.1y, *p*=0.009), showed reduce the survival risk and increase the survival probability. In contrast, the higher expression levels of 6 immunophenotypes indicators would increase survival risk and reduce survival probability. The 6 indicators were separately the percentage of effector memory CD4+ T cell (5.8y vs 7.5y, *p*=0.033), absolute number of effector CD8+ T cell (9.0y vs 9.1y, *p*=0.007), the percentage of activated CD8+ Tcells (6.7y vs 9.1y, *p*=0.006, absolute number of activated CD8+ T cells (8.9y vs 9.1y, *p*=0.035), the percentage of total monocyte(6.25y vs 9.1y, *p*=0.024) and the percentage of classical monocyte(5y vs 8.75y, *p*=0.026).

**Multivariable Cox regression analysis of overall survival of the acute ischemic stroke**

To further explore the relationship between different immunophenotypes indicators and survival probability, multivariable analyses of overall survival of the acute ischemic stroke were done. As shown in Figure 5,we can identified that 13 significant immunophenotypes indicators were selected by stepwise regression method. Among these 13 immunophenotypes indicators, there are 6 immunophenotypes indicators could increase survival risk, separately absolute number of TH cell(HR:11.13,95%CI:1.84-17.17, p =0.01), absolute number of naive CD8+ T cell(HR:1.31,95% CI:1.02-1.66, p =0.03), absolute number of CD16+ NK cells(HR:13.0,95% CI:6.00-18.98, p =0.01), absolute number of CD16- NK cells(HR:11.01,95% CI:1.90-13.64, p =0.01), the percentage of effector CD4+ T cell(HR:1.21,95% CI:1.02-1.40, p =0.02) and the percentage of naive CD8+ T cell(HR:1.09,95% CI:1.03-1.38, p =0.01).

**Discussion**

It is well known that there is not only an immediate pro-inflammatory response to stroke, but also post-stroke immunosuppression responses.12,13,14,15,16 In this study, we used a single-cell mass cytometry approach to analyze a large number of immunophenotypes indicators in peripheral blood with the systemic immune response within 24 hours after the acute ischemic stroke. 54 immunophenotypes indicators were statistically significant, especially T cells, monocytes, DC cells and Treg cells, indicated that a systemic immune response was inhibited significantly with the acute ischemic stroke after acute onset. In addition, inhibited immune response leading to poor survival in long-term significantly. More importantly, no one has comprehensively and systematically studied the relationship between peripheral blood immunophenotype indicators and the prognosis of acute ischemic stroke. This study aimed to discuss the importance of immunophenotype indicators which help doctors monitor patient outcomes in the acute ischemic stroke.

Many stroke patients experience severe consequences, however, reliably predicting stroke outcome remains challenging. Several attempts to identify characteristics associated with poor outcomes have been made. Almost 40% of stroke patients have a poor outcome at three months after the index event. Predictors for stroke outcome in the early acute phase may contribute to stroke treatment.17 The prognostic value of peripheral blood biomarkers in patients with the acute ischemic stroke could potentially be of great importance for clinical routine.

In our experiment, we found that 16 immunophenotypes indicators were relevant with the prognosis of acute ischemic stroke for univariate survival analysis (log-rank test, p<0.05). Besides, the relationship between different immunophenotypes indicators and survival probability were compared using multivariate survival analysis. 13 significant immunophenotypes indicators were selected by stepwise regression method. Peripheral blood of immunophenotypes indicators provide a promising and easily accessible biological substrate to search for such biomarkers and lay foundation on immunophenotypes and prognosis and survival after stroke.

Previous studies mainly focused on in humans18,19 and rodent models20 of the local and short-term immune response to stroke. However, the most studies are focused of animal models, it is hard to predict the situations in human. In contrast, from a clinical perspective, targeting inflammation in human may not be easy, especially for the long-term observations. Therefore, we proposed that using cytometry to analyze and compare the whole immunophenotypes indicators after acute ischemic stroke is possible and effective.

21-2425-2728,2930,313233,34Several lines of evidence suggested that immune responses detectable in peripheral blood relate to early innate and later adaptive immune responses in the brain.21-24 In our study, we focused on a large of immunophenotypes indicators of peripheral blood within 24 hours after acute ischemic stroke. More importantly, we found a strong correlation between immunophenotypes and survival probability of the acute ischemic stroke. For example, by calculating the HR of each immunophenotype indicator, as shown in **Figure 3**, 8 immunophenotypes indicators could decrease the survival probability and 8 immunophenotypes indicators could increase the survival probability in the acute ischemic stroke group. Besides, it was seen that the percentage of non-classical monocyte was the most significant immunophenotypes indicators with the survival probability. The absolute number of Th2 cell was the most significant indicators to increase the survival probability.

By analyzing immunophenotypes indicators of the peripheral blood in our studies, compared with the two groups of total T cell, we concluded that the acute ischemic stroke of it was lower than the control group. The percentage of and absolute number of total monocyte, non-classical monocyte and classical monocyte of the acute ischemic group were higher than the control group in our study.

Monocytes are a type of leukocytes that play an important role in the post-ischemic inflammation.35 Although only about 5% of white blood cells in peripheral blood are monocytes, these cells, as an important part of the vascular innate immune system, can produce large amounts of inflammatory cytokines.36 Hongbing Liu et al suggested that monocyte-to-high-density lipoprotein ratio (MHR) may be a significant and independent predictor of unfavorable functional outcome in patients with acute ischemic stroke.37 Besides, previous findings suggested that number of monocytes and plasma MCP-1 level could be clinical prognostic biomarkers as early predictors of disease outcome in patients with ischemic stroke.38 Monocytosis may also be an independent risk factor for myocardial infarction and cerebral ischemic disease and the monocyte count is also correlated with the National Institutes of Health Stroke Scale (NIHSS) score in patients with AIS.39,40 Xiaoyu Dong et al indicated that a peripheral monocyte count ≥0.53 × 109/L is an independent prognostic marker on 90-days in patients with acute ischemic stroke treated with rtPA thrombolysis.41 However, their study only examined peripheral blood monocytes, whereas we examined immunophenotype of all monocytes. In their study demonstrated that patients in the poor outcome group had a significantly higher monocyte count than those in the good outcome group. Consequently, it’s consistent with our results that indicated our research is more scientific and authentic.

3242

Furthermore, T cells may also affect various non-immunological pathways by interacting with brain-resident immune cells and modulating mechanisms such as neurogenesis and angiogenesis43.Therefore, the whole amount of T cells are crucial. In this study, we found both the percentage and absolute number of total T cells are significantly lower (*p*<0.001) after acute ischemic stroke than the control group. In addition, among all the ischemic stroke patients, lower total T cells also leading to lower survival rate, suggesting that T cells are involved in the progression and prognosis of stroke.

Regulatory T cells (Tregs) are a subpopulation of T cells that represents 5-10% of circulating CD4+T cells.44 Tregs that control inflammatory and immune responses in the body, are closely related to the pathogenesis of ischemic stroke. Tregs are crucially involved in the modulation of basal immunity, maintenance of immune homeostasis, and regulation of immune response to diseases.45 It was reported that after experimental stroke, the total number of peripheral blood T cells was significantly reduced, while the proportion of Tregs was significantly increased.46 Their results are consistent with ours. The proportion of Tregs in the peripheral blood was dramatically downregulated on day 1 after tMCAO, returning to normal amount on day 3 and to about 10% on day 7, which indicates the redistribution of Tregs post-stroke. It is speculated that Tregs migrate from the periphery to the brain in the early stage of stroke and exert early effects on cerebral ischemia through the peripheral immune system.47,48 49,50Besides, animal studies revealed that Tregs played a protective role in experimental stroke.51 Previous reports suggested that endogenous Tregs are neuro-protective and that boosting the number of circulating Tregs robustly protects against ischemic brain injury.46,52,53

54,553217

Dendritic cell (DC) is a type of cell involved in innate and adaptive immunity. In clinical studies, numbers of circulating DCs are inversely correlated with clinical stage and ischemic infarct size. 56 In agreement with the clinical studies, murine stroke models have also shown a strong correlation between brain parenchymal DCs and infarct volumes.57 Using flow cytometry, Gelderblom M, Leypoldt F, Steinbach K, et al have shown that DCs comprise a large portion of all infiltrating immune cells.58 Importantly, many studies suggest that DC amplification after cerebral ischemia exacerbates stroke outcomes.56 DCs present in the infarct zone could stimulate and activate T cells, induce a long-lasting immune response, and worsen stroke outcome. In addition, a transient decrease of DCs in the circulation might contribute to stroke-induced immunodepression.56

However, there are still limitations in this study, including that it was a retrospective study, and the immunophenotypes and cytokines such as IFN-γ in the peripheral blood should be analyzed continuously to better show the correlation with the prognosis. In addition, this study was limited to 1 hospital site, and limited sample size, which might restrict the generalizability of the results.59

In conclusion, our study lays the foundation for more comprehensive human studies in the future aimed at targeting specific markers and immunophenotype of peripheral blood. In addition, it was testified that answer the question of whether stroke-related phenotypical and functional immunological changes could be tracked in peripheral blood. The results demonstrated the utility of a deep immune profiling approach with single-cell mass cytometry to comprehensively and functionally characterize the systemic immune response within 24 hours after ischemic stroke in peripheral blood samples. Predictors of early acute stroke outcome may contribute to stroke treatment. The prognostic value of peripheral blood biomarkers in patients with the acute ischemic stroke may be of great significance to clinical routine.

**Declaration of interests**

The authors declare no competing financial interests.

**Acknowledgements**

We thank all the patients for their generous contribution to this study. This research was financially supported by National Natural Science Foundation of China (81971172 to YW , 31771392 to GBC), Zhejiang Provisional People’s Hospital Research Startup Fund (ZRY2018A004 to GBC), The Key Research and Development Program of Zhejiang Province (WKJ-ZJ-1914), Zhejiang Natural Science Foundation (LY18C09004), Medical and Health Science and Technology Project of Zhejiang Province (2018KY003, 2018KY816), Zhejiang Public Welfare Technology Research Program (LGF18H090009), and Analysis and Testing Technology Project of Zhejiang Provincial Department of Science and Technology (2018C37078 to LFZ) These funding bodies played no roles in the interpretation and the conduction of the research.

**Author contributions**

YW, Guo-Bo Chen, XMT conceived the study and designed the analysis, YW and KL curated the clinical data and the patients followed-up by telephone, Yong-Ran Cheng and Guo-Bo Chen performed [statistic](javascript:;)al [analysis](javascript:;), WMN conducted flow immunophenotype analysis. KL, Yong-Ran Cheng, WY, and Guo-Bo Chen wrote the first draft of the manuscript, and all other authors contributed to revision of the manuscript.

**Additional information**

Supplementary tables and figures can be found at the website of the journal.

References

1. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England) 2015;386:743-800.

2. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.

3. Gr?Schel K, Schnaudigel S, Edelmann F, et al. Growth-differentiation factor-15 and functional outcome after acute ischemic stroke. Journal of Neurology 2012;259:1574-9.

4. Tsai AS, Berry K, Beneyto MM, et al. A year-long immune profile of the systemic response in acute stroke survivors. Brain 2019;142:978-91.

5. Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Current opinion in neurology 2012;25:334-40.

6. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-7.

7. Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009;15:192-9.

8. Gee JM, Kalil A, Thullbery M, Becker KJ. Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke. Stroke 2008;39:1575-82.

9. Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009;40:1849-57.

10. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006;113:2105-12.

11. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012;12:191-200.

12. Dirnagl U, Klehmet J, Braun JS, Harms H, Meisel A. Stroke-induced immunodepression: experimental evidence and clinical relevance. Stroke 2007;38:770-3.

13. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nature Medicine 2012;17:796-808.

14. Chamorro Á, Meisel A, Planas A, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nature reviews Neurology 2012;8:401-10.

15. Chamorro Á, Meisel A, Planas AM, Urra X, Diederik VDB, Veltkamp R. The immunology of acute stroke. Nature Reviews Neurology 2012.

16. Doyle KP, Buckwalter MS. Does B lymphocyte-mediated autoimmunity contribute to post-stroke dementia? Brain Behavior and Immunity 2016:S088915911630366X.

17. Mengel A, Ulm L, Hotter B, Harms H, Hoffmann S. Biomarkers of immune capacity, infection and inflammation are associated with poor outcome and mortality after stroke - The PREDICT study. BMC Neurology 2019;19.

18. Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathologica 2004;108:524-30.

19. Doyle KP, Quach LN, Sole M, et al. B-Lymphocyte-Mediated Delayed Cognitive Impairment following Stroke. Journal of Neuroscience the Official Journal of the Society for Neuroscience 2015;35:2133-45.

20. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. Journal of Leukocyte Biology 2010;87.

21. Fassbender K, Schmidt R, Schreiner A, Fatar M, Hennerici M. Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. Journal of the Neurological Sciences 1997;148:101-5.

22. Becker KJ, Kindrick DL, Lester MP, Shea C, Ye ZC. Sensitization to brain antigens after stroke is augmented by lipopolysaccharide. J Cereb Blood Flow Metab 2005;25:1634-44.

23. Mayer CA, Brunkhorst R, Niessner M, et al. Blood levels of Glial Fibrillary Acidic Protein (GFAP) in patients with neurological diseases. Plos One 2013;8:e62101.

24. Chamorro Á, Dirnagl U, Urra X, Planas AM. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurology 2016:869-81.

25. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. British Journal of Pharmacology 2006;147 Suppl 1:S232-40.

26. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nature Reviews Neurology 2015.

27. Denes A, Vidyasagar R, Feng J, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2007;27:1941-53.

28. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998;56:149-71.

29. Denes A, Vidyasagar R, Feng J, et al. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab 2007;27:1941-53.

30. Gerhard A, Schwarz J, Myers R, Wise R, Banati RB. Evolution of microglial activation in patients after ischemic stroke: a [11C](R)-PK11195 PET study. Neuroimage 2005;24:591-5.

31. Price CJ, Wang D, Menon DK, et al. Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006;37:1749-53.

32. Popovi? N, Stefanovi?-Budimki? M, Mitrovi? N, et al. The frequency of poststroke infections and their impact on early stroke outcome. J Stroke Cerebrovasc Dis 2013;22:424-9.

33. Kim JS, Yoon SS, Yang HK, Jin SR. Serial Measurement of Interleukin-6, Transforming Growth Factor-β, and S-100 Protein in Patients With Acute Stroke. Stroke; a journal of cerebral circulation 1996;27:1553-7.

34. Bustamante A, Simats A, Vilar-Bergua A, García-Berrocoso T, Montaner J. Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics 2016;13:671-84.

35. Hamatani Y, Nagai T, Nakai M, et al. Elevated Plasma D-Dimer Level Is Associated With Short-Term Risk of Ischemic Stroke in Patients With Acute Heart Failure. Stroke 2018;49:1737-40.

36. Dutta P, Nahrendorf M. Monocytes in myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1066-70.

37. Liu H, Liu K, Pei L, et al. Monocyte-to-High-Density Lipoprotein Ratio Predicts the Outcome of Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis 2020;27:959-68.

38. David, Bonifai, Adrian, et al. Monocytes and monocyte chemoattractant protein 1 (MCP-1) as early predictors of disease outcome in patients with cerebral ischemic stroke. Wiener klinische Wochenschrift 2016;128:20-7.

39. Afiune Neto A, Mansur AP, Avakian S, Gomes E, Ramires J. [Monocytosis is an independent risk marker for coronary artery disease]. Arquivos brasileiros de cardiologia 2006;86:240-4.

40. Muichi K, Shin-Ichi A, Yuichiro G, et al. Relevance of Distinct Monocyte Subsets to Clinical Course of Ischemic Stroke Patients. Plos One 2013;8:e69409.

41. Dong X, Nao J, Gao Y. Peripheral Monocyte Count Predicts Outcomes in Patients with Acute Ischemic Stroke Treated with rtPA Thrombolysis. Neurotoxicity research 2020;37:469-77.

42. Schmidt A, Strecker JK, Hucke S, Bruckmann NM, Minnerup J. Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke. Stroke 2017;48:1061.

43. Cramer JV, Benakis C, Liesz A. T cells in the post-ischemic brain: Troopers or paramedics? J Neuroimmunol 2019;326:33-7.

44. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. Journal of Immunology 2006;177:8338-47.

45. Pankratz S, Ruck T, Meuth SG, Wiendl H. CD4+HLA-G+ regulatory T cells: Molecular signature and pathophysiological relevance. Human Immunology 2016.

46. Liesz A, Zhou W, Na SY, et al. Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. Journal of Neuroscience the Official Journal of the Society for Neuroscience 2013;33:17350.

47. Stubbe T, Ebner F, Richter D, et al. Regulatory T cells accumulate and proliferate in the ischemic hemisphere for up to 30 days after MCAO. Journal of Cerebral Blood Flow & Metabolism 2013;33:37-47.

48. Kleinschnitz C, Kraft P, Dreykluft A, et al. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood 2012;121:679-91.

49. Ishibashi S, Maric D, Mou Y, Ohtani R, Ruetzler C, Hallenbeck JM. Mucosal tolerance to E-selectin promotes the survival of newly generated neuroblasts via regulatory T-cell induction after stroke in spontaneously hypertensive rats. Journal of Cerebral Blood Flow & Metabolism Official Journal of the International Society of Cerebral Blood Flow & Metabolism 2009;29:606-20.

50. Urra X, Cervera A, Villamor N, Planas AM, Chamorro A. Harms and benefits of lymphocyte subpopulations in patients with acute stroke. Neuroscience 2009;158:1174-83.

51. Liesz A, Suri-Payer E, Veltkamp C, et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nature Medicine 2009;15:192-9.

52. Li P, Gan Y, Sun BL, et al. Adoptive Regulatory T-Cell Therapy Protects Against Cerebral Ischemia. Annals of Neurology 2013;74.

53. Brea D, Agulla J, Rodríguez-Yáñez M, et al. Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia. Journal of Cellular and Molecular Medicine 2014.

54. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke; a journal of cerebral circulation 2003;34:122-6.

55. Saposnik G, Hill MD, O"Donnell M, Fang J, Hachinski V, Kapral MK. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke 2008;39:2318-24.

56. Yilmaz A, Fuchs T, Dietel B, et al. Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain. Clinical Science 2009;118:147-57.

57. Kostulas N, Li H, Xiao B, Huang Y, Kostulas V, Link H. Dendritic cells are present in ischemic brain after permanent middle cerebral artery occlusion in the rat. Stroke 2002;33:1129-34.

58. Gelderblom M, Leypoldt F, Steinbach K, et al. Temporal and Spatial Dynamics of Cerebral Immune Cell Accumulation in Stroke. 2009.

59. Felger JC, Abe T, Kaunzner UW, et al. Brain dendritic cells in ischemic stroke: Time course, activation state, and origin. Brain Behavior & Immunity 2010;24:724-37.

**Figure legends**

**Figure 1 Flowchart of the study.**

**Figure 2 Prognostic incidence of overall survival curve comparisons between patients with the acute ischemic stroke and the control group**

**Figure 3 Typical immunophenotypes indicators of** Univariate Cox survival analysis conditions in the acute ischemic stroke

**Figure 4 Effects of high and low immunophenotypes indicators (According to the mean value) on survival and prognosis in the acute ischemic stroke.**

**Figure S1 Distribution of immunophenotypes indicators difference between the control group and the acute ischemic group.**

**Figure S2** **54 immunophenotypes indicators of clinical Statistical significance by** Univariate Cox survival **survival conditions in the acute ischemic stroke group.**

**Figure S3 16 immunophenotypes indicators between the acute ischemic stroke and the control group.**

**Figure S4 Effects of high and low 54 immunophenotypes indicators of clinical Statistical significance by** Univariate Cox survival **survival conditions in the acute ischemic stroke group.**

**Figure 5 Multivariate Cox survival analysis in the ischemic stroke**

**Table 1 Characteristics of study participants**

**Table 2 Characteristics of Immunophenotype between patients with the acute ischemic stroke and the control group**

**Table S1 Detection scheme for eight-color antibody panels proposed by the Human Immunophenotyping Consortium**

1. Gr?Schel K, Schnaudigel S, Edelmann F, et al. Growth-differentiation factor-15 and functional outcome after acute ischemic stroke. Journal of Neurology 2012;259:1574-9.